MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Amneal Pharmaceuticals Book Value 2011-2026 | AMRX
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Amneal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.68 B | 3.5 B | 3.47 B | 3.8 B | 3.94 B | 4.01 B | 347 M | 896 M | -376 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.01 B | -376 M | 2.58 B |
Quarterly Book Value Amneal Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 3.8 B | 3.87 B | 4.04 B | 3.89 B | 3.94 B | 3.97 B | 4.02 B | 3.96 B | 4.01 B | 4.01 B | 4.01 B | 4.01 B | 3.67 B | 3.67 B | 3.67 B | 3.67 B | 4.35 B | 4.35 B | 4.35 B | 4.35 B | 1.34 B | 1.34 B | 1.34 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.35 B | 1.34 B | 3.64 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
30.6 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Axsome Therapeutics
AXSM
|
88.3 M | $ 163.89 | - | $ 8.15 B | USA |
 |
BridgeBio Pharma
BBIO
|
-2.08 B | $ 64.28 | -3.31 % | $ 12.3 B | USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
BioCardia
BCDA
|
-1.6 M | $ 1.37 | 5.81 % | $ 29 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
5.36 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
BioLineRx Ltd.
BLRX
|
13.5 M | $ 2.82 | -0.35 % | $ 908 M |  Israel |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioMarin Pharmaceutical
BMRN
|
6.09 B | $ 59.8 | -3.13 % | $ 11.5 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
18.5 B | $ 62.08 | -0.46 % | $ 126 B | USA |
 |
Benitec Biopharma
BNTC
|
97.3 M | $ 10.93 | 0.23 % | $ 450 M | USA |
 |
BioNTech SE
BNTX
|
19.4 B | $ 109.33 | -0.82 % | $ 27.2 B | Germany |
 |
Black Diamond Therapeutics
BDTX
|
83.3 M | $ 2.38 | -3.44 % | $ 131 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-93.1 M | $ 1.63 | -2.4 % | $ 4.13 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Burford Capital Limited
BUR
|
1.66 B | $ 8.65 | 2.49 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
BeyondSpring
BYSI
|
-14.3 M | $ 1.34 | -0.87 % | $ 54 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
236 M | $ 3.34 | 0.61 % | $ 3.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
113 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 4.88 | 2.74 % | $ 10.6 B | Israel |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Capricor Therapeutics
CAPR
|
22.6 M | $ 27.28 | -2.32 % | $ 731 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
Catalyst Biosciences
CBIO
|
78.5 M | $ 11.67 | -3.47 % | $ 768 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
C4 Therapeutics
CCCC
|
257 M | $ 3.06 | 13.3 % | $ 254 M | USA |
 |
Aptose Biosciences
APTO
|
-4.54 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Athira Pharma
ATHA
|
44.8 M | - | - | $ 269 M | USA |
 |
Codexis
CDXS
|
66.9 M | $ 0.99 | -2.04 % | $ 72.7 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-24.2 M | - | 17.91 % | $ 11.1 M | USA |